BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced Malignancies

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BAY1000394

First Posted Date: 2011-04-14

Last Posted Date: 2013-05-03

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT01335256

Observational Program Neo-Penotran® Forte

Completed

Conditions: Vaginal Candidiasis
Bacterial Vaginosis
Trichomonal Vaginitis

Interventions: Drug: Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)

First Posted Date: 2011-04-14

Last Posted Date: 2016-07-25

Lead Sponsor: Bayer

Target Recruit Count: 13024

Registration Number: NCT01335373

Influence of Different Approaches to Dietary Advising on the Effects of Acarbose Treatment in Obese Diabetic Patients Under Real-life Setting

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Glucobay (Acarbose, BAYG5421)

First Posted Date: 2011-04-12

Last Posted Date: 2012-05-04

Lead Sponsor: Bayer

Target Recruit Count: 423

Registration Number: NCT01333774

Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)

Phase 1

Completed

Conditions: Anemia

Interventions: Drug: BAY85-3934

First Posted Date: 2011-04-11

Last Posted Date: 2015-07-14

Lead Sponsor: Bayer

Target Recruit Count: 44

Registration Number: NCT01332942

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

Phase 3

Completed

Conditions: Macular Edema
Diabetes Mellitus

Interventions: Biological: VEGF Trap-Eye (BAY86-5321)
Procedure: Macular Laser Photocoagulation (Control)

First Posted Date: 2011-04-08

Last Posted Date: 2023-11-27

Lead Sponsor: Bayer

Target Recruit Count: 406

Registration Number: NCT01331681

Locations: 🇩🇪
Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Rheinland-Pfalz, Germany
🇮🇹
IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
🇫🇷
Hopital Lariboisiere, Paris, France

and more 1 locations

Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America

Phase 3

Withdrawn

Conditions: Contraception

Interventions: Drug: EE20/DRSP (BAY86-5300)
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071)

First Posted Date: 2011-04-08

Last Posted Date: 2014-07-15

Lead Sponsor: Bayer

Registration Number: NCT01331655

Effects of Phenylephrine on Nasal Congestion in Participants With Seasonal Allergic Rhinitis (P08156 AM2)(Completed)

Phase 2

Completed

Conditions: Seasonal Rhinitis
Rhinitis

Interventions: Drug: Phenylephrine HCl
Drug: Placebo
Drug: Loratadine

First Posted Date: 2011-04-06

Last Posted Date: 2015-03-11

Lead Sponsor: Bayer

Target Recruit Count: 539

Registration Number: NCT01330017

Essure Transvaginal Ultrasound (TVU) Study

Phase 4

Completed

Conditions: Contraceptive Usage

Interventions: Device: TVU

First Posted Date: 2011-04-01

Last Posted Date: 2023-08-03

Lead Sponsor: Bayer

Target Recruit Count: 547

Registration Number: NCT01327105

Effect of Rifampin on the Pharmacokinetics of BAY73-4506

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (BAY73-4506) + rifampin

First Posted Date: 2011-03-24

Last Posted Date: 2014-12-19

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT01322438

Effect of Piroxicam on Ovulation

Phase 2

Completed

Conditions: Contraception, Postcoital

Interventions: Drug: Piroxicam ( BAYl1902)
Drug: Placebo

First Posted Date: 2011-03-22

Last Posted Date: 2015-07-10

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT01320709

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy